Literature DB >> 29026008

Abdominal obesity and colorectal cancer risk: systematic review and meta-analysis of prospective studies.

Yunlong Dong1, Jiao Zhou2, Yun Zhu3, Linhai Luo1, Tao He1, Hong Hu1, Hao Liu4, Yingliang Zhang1, Dan Luo5, Shuanglan Xu6, Lifen Xu7, Jianping Liu8, Jun Zhang9, Zhaowei Teng10.   

Abstract

The association between abdominal obesity (as measured by waist circumference (WC) and waist-to-hip ratio (WHR)) and colorectal cancer (CRC) has not been fully quantified, and the magnitude of CRC risk associated with abdominal obesity is still unclear. A meta-analysis of prospective studies was performed to elucidate the CRC risk associated with abdominal obesity. Pubmed and Embase were searched for studies assessing the association between abdominal obesity and CRC risk. Relative risks (RRs) with 95% confidence intervals (95% CIs) were pooled using random-effects model of meta-analysis. Nineteen prospective cohort studies from eighteen publications were included in this meta-analysis. A total of 12,837 CRC cases were identified among 1,343,560 participants. Greater WC and WHR were significantly associated with increased risk of total colorectal cancer (WC: RR 1.42, 95% CI 1.30, 1.55; WHR: RR 1.39, 95% CI 1.25, 1.53), colon cancer (WC: RR 1.53, 95% CI 1.36, 1.72; WHR: 1.39, 95% CI 1.18, 1.63), and rectal cancer (WC: RR 1.20, 95% CI 1.03, 1.39; WHR: RR 1.22, 95% CI 1.05, 1.42). Subgroup analyses further identified the robustness of the association above. No obvious risk of publication bias was observed. In summary, abdominal obesity may play an important role in the development of CRC.
© 2017 The Author(s).

Entities:  

Keywords:  abdominal obesity; central obesity; colorectal cancer; waist circumference; waist to hip ratio

Mesh:

Year:  2017        PMID: 29026008      PMCID: PMC5725611          DOI: 10.1042/BSR20170945

Source DB:  PubMed          Journal:  Biosci Rep        ISSN: 0144-8463            Impact factor:   3.840


Introduction

Colorectal cancer (CRC) is a major public health concern, as it is one of the leading causes of cancer deaths in the Western world [1]. Although the high incidence rate of CRC is observed in developed countries, its incidence rate has been rapidly increasing in developing countries over the last few decades [2]. To explore the effective tools for the prevention of CRC, great investment has been made to gain new insight into how environmental factors influence the development of CRC. Several environmental risk factors, such as smoking, obesity, a high-fat/low-fiber diet or physical inactivity, have been suggested for CRC development [3-5]. The prevalence of overweight and obesity is increasing dramatically in most parts of the world, and can lead to obesity-related cancers, including postmenopausal breast cancer, colorectal, endometrial, esophagus, kidney, lung, pancreatic, thyroid, and gallbladder cancers [6-14]. However, the association between obesity and CRC is controversial. In contrast with general obesity, body fat distribution—particularly abdominal obesity—appears to play a role in the development of CRC [15,16]. This positive association of WC or WHR with CRC remained even after adjustment for body mass index (BMI) [15,17,18]. The risk of CRC in obese individuals, especially those with higher abdominal obesity has not been fully quantified, and it is also unclear whether abdominal obesity is an independent risk factor of CRC. Therefore, a comprehensive systematic review and meta-analysis of prospective studies was performed to estimate the risk of CRC associated with abdominal obesity.

Materials and methods

Search strategy

The present study was planned, conducted, and reported in adherence to the “Meta-Analysis of Observational Studies in Epidemiology (MOOSE)” guidelines [19]. We systematically searched Pubmed and Embase (from their commencements to April 28, 2017) for studies of the association between abdominal obesity and colorectal cancer risk. We used the following search terms: (obesity OR adiposity OR body size OR body fat distribution OR anthropometric OR anthropometry OR waist-to-hip ratio OR WHR OR waist circumference OR WC) AND (colorectal cancer OR colorectal neoplasm OR colon cancer OR colon neoplasm OR rectal cancer OR rectal neoplasm) AND (cohort OR prospective OR follow-up). The search strategy had no language, publication date, or publication type restriction. In addition, the reference lists of relevant reviews or included articles were also searched to find other eligible studies.

Study selection

Studies were included if they met all of the following criteria: (a) prospective cohort studies; (b) the exposure of interest was abdominal obesity (measured using WC and/or WHR); (c) the outcome of interest was colorectal cancer; (d) risk estimates of colorectal cancer associated with abdominal obesity were available, such as relative risks (RRs) or hazard ratios (HRs) with 95% confidence intervals (CIs); and (e) the risk estimates were adjusted for other confounding factors. Studies were excluded if they focused on colorectal mortality or recurrence.

Data extraction and quality assessment

Using a standardized extraction form, the following data were extracted from each study: the first author’s last name, publication year, country, study period, age range, sex, number of cases, number of participants, data collection, measures of abdominal adiposity, cancer sites, most fully adjusted risk estimates with their corresponding 95% CIs for each category of abdominal adiposity measures, and adjustment for potential confounding factors. Risk estimates reported by gender were extracted separately. Newcastle–Ottawa Scale (NOS) was used to assess the quality of included studies [20]. According to the quality criteria, four points were awarded for the selection of the study groups (representativeness, selection of non-exposed cohort, ascertainment of exposure, and no disease at start of study), two points for the comparability of groups, and three points for the assessment of outcomes (assessment of outcome, length of follow-up, and adequacy of follow-up). Quality was assigned as excellent with seven to nine stars, good with four to six stars, and suboptimal with zero to three stars. Two investigators (Y.L.D. and Z.W.T.) participated in literature search, study selection, data extraction, and quality assessment independently. Disagreements were resolved by discussion.

Statistical analysis

HR was directly considered as RR across the present study. The pooled RRs with 95% CIs were calculated using a random-effects model with the method of DerSimonian and Laird [21]. Because WC and WHR are different among races and studies, and have no unified criteria around the world, we combined the different outcomes between the smallest WC or WHR quantile and the largest WC or WHR quantile in studies using relative risks in meta-analysis of random effects. The degree of heterogeneity in the relationship between measures of abdominal obesity and colorectal cancer across studies was assessed using Q and I2 statistics. For the Q statistic, P<0.1 was considered statistically significant; and for the I2 statistic, I2 more than 40% indicated substantial heterogeneity across included studies, and metaregression was further utilized to find the source of heterogeneity. Both Begg’s and Egger’s tests were performed to investigate potential publication bias [22,23]. To explore potential sources of heterogeneity, subgroup analyses were performed by anatomical subsite, geographic region, sex, and data collection. To evaluate the effect of an individual article on the overall pooled results, a sensitivity analysis was conducted by omitting each article from the overall analysis in every turn. All statistical analyses were performed using STATA, version 12.0 (STATA Corp., College Station, Texas, U.S.A.). A two-tailed P-value of less than 0.05 was considered to be statistically significant.

Results

Literature search

A total of 714 articles were initially identified from Pubmed and Embase databases. After removing the duplicated articles, 382 studies were included for further assessment. Of these articles, 355 studies were excluded after reading the titles and the abstracts. After full-text review of the remaining 27 articles, 18 studies [15,17,18,24-38] were included in the final meta-analysis (Figure 1). Four [35-38] of the eighteen articles were identified from references of three full-text articles.
Figure 1

Flow chart of study selection in the meta-analysis

.

Flow chart of study selection in the meta-analysis

.

Study characteristics

The general characteristics of the included studies are presented in Table 1. The included studies which were published from 1994 to 2015 were all prospective cohort studies. There were 12,837 colorectal cancer cases among 1,343,560 participants. Of these 18 studies, 1 was conducted in Asia [26], 11 in the U.S.A. [15,17,24,25,27,28,33,34,36-38], 3 in Europe [18,29,35], and 3 in Australia [30-32]. Among the studies, 3 concerned about men [15,29,32], 6 about women [17,24,27,31,34,37], and 9 about both genders [18,25,26,28,30,33,35,36,38]. Nine studies relied on self-reported data [15,17,25,27-29,34,35,37], and 10 studies relied on measured data [18,24,26,30-33,35,36,38]. Individual studies adjusted for a wide range of potential confounding factors, such as age, physical activity, and alcohol intake. The details of quality assessment according to the nine-star NOS are presented in the online Supplementary Table S1. All studies were given scores of ≥6.
Table 1

Baseline characteristics of the included studies

StudyStudy periodAge rangeSexCases/Cohort sizeData collectionCancer sitesMeasure of adiposityCategories, highest vs. lowest (measurement unit)Adjusted RR (95% CI)Adjustments
Moore (ages 30–54 y) (2004) U.S.A. [33]1948–199930–54M/F157/3764MeasuredCCWCMen: <83.8 cm vs. ≥101.6 cmCC: 2.9 (1.2–6.7)BMI, sex, education, age, height, alcohol intake, cigarettes per day, physical activity
CC: men 3.3 (0.91–12.3); women 2.3 (0.74–7.0)
Women: <81.3 cm vs. ≥99.1 cmProximal CC: 3.0 (1.0–8.6)
Distal CC: 2.5 (0.59–10.6)
Moore (ages 55–79 y) (2004) U.S.A. [33]1948–199955–79M/F149/3802MeasuredCCWCMen: <83.8 cm vs. ≥101.6 cmCC: 2.4 (1.0–5.6)BMI, education, age, height, alcohol intake, cigarettes per day, physical activity
CC: men 3.0 (0.86–10.3); women 2.1 (0.63–6.7)
Women: <81.3 cm vs. ≥99.1 cmProximal CC: 2.4 (0.78–7.1)
Distal CC: 2.4 (0.62–9.2)
Larsson (2006) Sweden [29]1998–200545–79M496/45906Self-reportCC/RC/CRCWCMen: <88 cm vs. ≥104 cmCRC: men 1.29 (0.90–1.85)Age, education, family history of colorectal cancer, history of diabetes, smoking, aspirin use, leisure-time physical activity, height
CC: men 1.44 (0.93–2.24)
Proximal CC: men 1.66 (0.84–3.27)
Distal CC: men 1.62 (0.80–3.27)
RC: men 1.24 (0.68–2.25)
Pischon (2006) Europe [18]1992–200025–70M/F1570/368277MeasuredCC/RCWCMen: <86.0 cm vs. ≥103.0 cmCC: men 1.39 (1.01–1.93); women 1.48 (1.08–2.03)Age, center and age at recruitment, smoking status, education, alcohol intake, physical activity, fiber intake, consumption of red and processed meat, fish and shellfish, fruits and vegetables, height
Women: <70.2 cm vs. ≥89.0 cmRC: men 1.27 (0.84–1.91); women 1.23 (0.81–1.86)
WHRMen: <0.887 vs. ≥0.990CC: men 1.51 (1.06–2.15); women 1.52 (1.12–2.05)
Women: <0.734 vs. ≥0.846RC: men 1.93 (1.19–3.13); women 1.20 (0.81–1.79)
Maclnnis (2005) Australia [31]1990–200327–75F212/24072MeasuredCCWCWomen: <80 cm vs. ≥88 cmCC: women 1.4 (1.0–1.9)Country of birth, highest level of education, hormone replacement therapy use
WHRWomen: <0.75 vs. ≥0.80CC: women 1.7 (1.1–2.4)
Giovannucci (1995) U.S.A. [15]1987–199240–75M203/47723Self-reportCCWCMen: <35 in vs. ≥43 inCC: men 2.56 (1.33–4.96)Age, history of endoscopic screening, previous polyp diagnosis, parental history of colorectal cancer, pack-years of smoking, physical activity, aspirin use, and intake of folate, methione, alcohol, dietary fiber, total energy, and red meat
WHRMen: <0.90 vs. ≥0.99CC: men 3.41 (1.52–7.66)
Martinez (1997) U.S.A. [17]1986–199230–55F212/67802Self-reportCCWCWomen: ≤27.5 in vs. >34 inCC: women 1.48 (0.89–2.46)ND
Distal CC: women 1.47 (0.71–3.06)
WHRWomen: <0.728 vs. >0.833CC: women 1.48 (0.88–2.49)Age, cigarette smoking, family history of colorectal cancer, leisure-time physical activity, postmenopausal hormone use, aspirin use, intake of red meat, and alcohol consumption
Proximal CC: women 1.66 (0.69–3.99)
Distal CC: women 1.79 (0.82–3.90)
Bostick (1994) U.S.A. [34]1986–199055–69F212/35215Self-reportCCWHRWomen: <0.764 vs. >0.906CC: women 1.25 (0.83–1.88)Age, total energy intake, height, parity, total vitamin E intake, a total vitamin E by age interaction term, and vitamin A supplement intake
Maclnnis (2004) Australia [32]1991–200227–75M153/16556MeasuredCCWCMen: <87.0 cm vs. >99.3 cmCC: men 2.1 (1.3–3.5)Age at attendance, country of birth, highest level of education
WHRMen: <0.88 vs. >0.96CC: men 2.1 (1.3–3.4)
Wang (2008) U.S.A. [28]1997–2005≥45M/F953/95151Self-reportCC/RC/CRCWCMen: <95 cm vs. ≥120 cmCRC: men 1.68 (1.12–2.53); women 1.75 (1.20–2.54)Height, education, physical activity, smoking, alcohol intake, NSAID use, multivitamin use, and history of colorectal endoscopy (women+HRT use)
Women: <85 cm vs. ≥110 cmCC: men 2.05 (1.29–3.25); women 1.54 (1.00–2.37)
RC: men 1.02 (0.43–2.42); women 2.65 (1.23–5.71)
Oxentenko (2010) U.S.A. [27]1986–200555–69F1464/36941Self-reportCRCWCWomen: ≤77.15 cm vs. ≥96.53 cmCRC: women 1.32 (1.11–1.56)Age at baseline, age at menopause, exogenous estrogen use, oral contraceptive use, smoking status, cigarette pack-years, physical activity level, self-reported diabetes mellitus, and intake of total energy, total fat, red meat, fruits and vegetables, calcium, folate, vitamin E and alcohol
WHRWomen: ≤0.78 vs. ≥0.90CRC: women 1.28 (1.08–1.50)
Li (2013) China [26]1997–200940–74M/F935/134255MeasuredCC/RC/CRCWCMen: <78 cm vs. ≥92 cmCRC: men 1.38 (0.97–1.97); women 1.26 (0.93–1.72)Age at baseline, education, income, pack-years of cigarette use, tea consumption, alcohol consumption, physical activity, family history of colorectal cancer and intakes of total energy, red meat, fruits and vegetables
Women: <70 cm vs. ≥85 cmCC: men 2.00 (1.21–3.29); women 1.34 (0.89–2.00)
RC: men 0.88 (0.52–1.49); women 1.17 (0.73–1.88)
WHRMen: <0.85 vs. ≥0.95CRC: men 1.65 (1.12–2.41); women 1.01 (0.79–1.31)
Women: <0.77 vs. ≥0.85CC: men 1.97 (1.19–3.24); women 0.96 (0.69–1.34)
RC: men 1.24 (0.69–2.26); women 1.11 (0.74–1.66)
Keimling (2013) U.S.A. [25]1995–200650–71M/F2869/203177Self-reportCC/RCWCMen: <89.5 cm vs. ≥106.5 cmCC: men 1.45 (1.16–1.82); women 0.90 (0.63–1.27)Age, education, race/ethnicity, smoking status, marital status, physical activity, NSAID use, family history of colorectal cancer, diabetes status, dietary intakes of total energy, fiber, folate, calcium, red meat, fruits and vegetables, alcohol, HRT, height (WC+hip circumference)
Women: <73.6 cm vs. ≥94.5 cmProximal CC: women 0.86 (0.56–1.32)
Distal CC: women 1.00 (0.54–1.84)
RC: men 0.97 (0.67–1.38); women 1.01 (0.53–1.94)
WHRMen: <0.898 vs. ≥1.000CC: men 1.29 (1.10–1.52); women 0.90 (0.70–1.15)
Women: <0.746 vs. ≥0.877Proximal CC: women 0.73 (0.53–1.01)
Distal CC: women 1.23 (0.80–1.90)
RC: men 1.08 (0.82–1.43); women 1.13 (0.69–1.86)
Kabat (2015) U.S.A. [24]1993–201350–79F1908/143901MeasuredCRCWCNDCRC: women 1.90 (1.61–2.25)Age, alcohol, smoking, hormone therapy, MET-hours/week, aspirin intake, diabetes, family history of colorectal cancer in a first-degree relative, education, ethnicity, treatment allocation
WHRNDCRC: women 1.65 (1.40–1.93)
Park (2011) U.K. [35]1993–200640–79M/F357/24244Measured self-reportCRCWCMen: <88.0 cm vs. ≥103.3 cmMeasured CRC: men 0.86 (0.55–1.36); women 1.65 (0.97–2.86)Age, sex, smoking, alcohol, education, exercise, family history of CRC, energy intake, folate, fiber, total meat and processed meat, intakes, height
Women: <73.0 cm vs. ≥90.5 cmSelf-report CRC: men 0.95 (0.54–1.64); women 1.42 (0.85–2.35)
WHRMen: <0.883 vs. ≥0.979Measured CRC: men 1.34 (0.79–2.25); women 2.07 (1.17–3.67)
Women: <0.739 vs. ≥0.844Self-report CRC: men 1.79 (0.88–3.62); women 1.26 (0.75–2.13)
Folsom (2000) U.S.A. [37]1986–199655–69F462/31702Self-reportCCWCWomen: <74.3 cm vs. ≥96.0 cmCC: women 1.6 (1.2–2.2)Age, educational level, physical activity, alcohol intake, smoking status, pack-years of cigarette smoking, age of first live birth, estrogen use, vitamin use, and energy, whole grain, fruit and vegetable, fish, and red meat intake and keys score
WHRWomen: <0.762 vs. ≥0.901CC: women 1.2 (0.9–1.7)
Schoen (1999) U.S.A. [38]1989–1996≥65M/F102/5849MeasuredCRCWCMen: 69–91 cm vs. 104.1–145.5 cmCRC: 2.2 (1.2–4.1)Age, sex, and physical activity
Women: 32.5–82 cm vs. 101.2–167 cm
WHRMen: 0.61–0.93 vs. 1.01–2.33CRC: 2.6 (1.4–4.8)
Women: 0.61–0.83 vs. 0.961–2.06
MacInnis (2006) Australia [30]1990–200327–75M/F229/41114MeasuredRCWCMen: <94 cm vs. ≥102 cmRC: 1.4 (1.0–1.9)Age as the time axis, sex, and country of birth
Women: <80 cm vs. ≥88 cmRC: men 1.4 (0.9–2.2); women 1.4 (0.8–2.2)
WHRMen: <0.90 vs. ≥0.95RC: 1.3 (0.9–1.8)
Women: <0.75 vs. ≥0.80RC: men 1.2 (0.8–1.8); women 1.4 (0.8–2.4)
Ahmed (2006) U.S.A. [36]1987–200045–64M/F194/14109MeasuredCRCWCMen: <102 cm vs. ≥102 cmCRC: 1.40 (1.0–1.9)Family history of colorectal cancer, physical activity, nonsteroidal anti-inflammatory drug use, aspirin use, pack-years of cigarette use, and grams of alcohol per week (women+HRT use)
Women: <88 cm vs. ≥88 cm

Abbreviations: 95% CI, 95% confidence interval; BMI, body mass index; CC, colon cancer; CRC, colorectal cancer; F, female; HRT, hormone replacement therapy; M, male; ND, no data; RC, rectal cancer; RR, relative risk; WC, waist circumference; WHR, waist-to-hip ratio.

Abbreviations: 95% CI, 95% confidence interval; BMI, body mass index; CC, colon cancer; CRC, colorectal cancer; F, female; HRT, hormone replacement therapy; M, male; ND, no data; RC, rectal cancer; RR, relative risk; WC, waist circumference; WHR, waist-to-hip ratio.

WC and colorectal cancer

Eighteen prospective cohort studies [15,17,18,24-33,35-38] were included in the analysis of WC and risk of colorectal cancer incidence. Comparison of the highest category of WC with the lowest category revealed significant associations between greater WC and increased risk of total colorectal cancer (RR 1.42, 95% CI 1.30, 1.55), colon cancer (RR 1.53, 95% CI 1.36, 1.72), and rectal cancer (RR 1.20, 95% CI 1.03, 1.39) (Figure 2a). The evidence of moderate heterogeneity were observed for total colorectal cancer (I2 = 40.1%, P=0.015), while low heterogeneity was observed for colon cancer (I2 = 24.6%, P=0.176). On the other hand, no evidence of heterogeneity for rectal cancer (I2 = 0.0%, P=0.518). Subgroup analyses further identified the robustness of the association between abdominal obesity and CRC risk (Table 2). Stratifying by sex, the pooled RRs of CRC from male and female CRC studies for the highest vs. lowest categories of WC level were 1.38 (95% CI, 1.19–1.59) and 1.44 (95% CI, 1.28–1.61) respectively. Stratifying by geographic region, the pooled RRs of CRC for the highest vs. lowest categories of WC level were 1.31 (95% CI, 1.04–1.65) for studies conducted in Asia, 1.50 (95% CI, 1.30–1.74) for studies in the United States, 1.29 (95% CI, 1.13–1.48) for studies in Europe, and 1.51 (95% CI, 1.22–1.87) for studies in Australia. When we stratified the analysis by measured and self-reported CRC data, the pooled RRs of measured and self-reported CRC data were 1.48 (95% CI, 1.32–1.67) and 1.35 (95% CI, 1.18–1.53) for the highest vs. lowest categories of WC levels respectively. Metaregression analysis showed that geographic region was the source of heterogeneity. The sensitivity analyses omitting one study at a time and calculating the combined RRs for the remaining studies showed that the combined RRs were not substantially affected by any single study (Figure 3a). The Begg’s and Egger’s tests indicated no evidence of publication bias among the studies [Begg, P > |z| = 0.431; Egger, P = 0.862, 95% CI, 1.402–1.181] (Figure 4a).
Figure 2

(a) Pooled relative risk of CRC associated with waist circumference; (b) Pooled relative risk of CRC associated with waist-to-hip ratio.

Table 2

Subgroup analyses of CRC risk associated with abdominal obesity

SubgroupWCWHR
StudiesRR (95% CI)Heterogeneity (P-value, I2)StudiesRR (95% CI)Heterogeneity (P-value, I2)
Anatomical subsite
Colorectal cancer181.42 (1.30–1.55)0.015, 40.1%141.39 (1.25–1.53)0.002, 51.2%
Colon cancer121.53 (1.36–1.72)0.176, 24.6%91.39 (1.18–1.63)0.004, 60.2%
Rectal cancer61.20 (1.03–1.39)0.518, 0.0%41.22 (1.05–1.42)0.591, 0.0%
Geographic region
Asia11.31 (1.04–1.65)0.704, 0.0%11.26 (0.78–2.04)0.036, 77.2%
U.S.A.111.50 (1.30–1.74)0.002, 58.6%81.32 (1.13–1.54)0.001, 66.3%
Europe31.29 (1.13–1.48)0.628, 0.0%21.51 (1.29–1.76)0.741, 0.0%
Australia31.51 (1.22–1.87)0.345, 6.0%31.61 (1.23–2.10)0.260, 25.8%
Sex
Colorectal cancer
Men111.38 (1.19–1.59)0.088, 36.0%71.47 (1.25–1.73)0.083, 41.2%
Women131.44 (1.28–1.61)0.075, 36.1%111.30 (1.15–1.48)0.012, 52.0%
Colon cancer
Men91.67 (1.43–1.94)0.366, 8.3%51.71 (1.29–2.27)0.039, 60.3%
Women91.39 (1.21–1.60)0.392, 5.2%71.22 (1.01–1.48)0.044, 53.6%
Rectal cancer
Men61.12 (0.92–1.36)0.717, 0.0%41.27 (0.99–1.62)0.242, 28.4%
Women51.31 (1.03–1.67)0.376, 5.4%41.19 (0.95–1.49)0.920, 0.0%
Data collection
Measured111.48 (1.32–1.67)0.069, 36.9%81.53 (1.34–1.75)0.056, 41.8%
Self-report81.35 (1.18–1.53)0.086, 37.2%71.22 (1.08–1.38)0.122, 34.6%

Abbreviations: CI, confidence interval; RR, relative risk; WC, waist circumference; WHR, waist-to-hip ratio.

Figure 3

(a) Sensitivity analysis of CRC associated with waist circumference; (b) Sensitivity analysis of CRC associated with waist-to-hip ratio.

Figure 4

(a) Both Begg’s rank correlation test and Egger’s linear regression test of CRC associated with waist circumference; (b) Both Begg’s rank correlation test and Egger’s linear regression test of CRC associated with waist-to-hip ratio.

Abbreviations: CI, confidence interval; RR, relative risk; WC, waist circumference; WHR, waist-to-hip ratio.

WHR and colorectal cancer

Fourteen prospective cohort studies [15,17,18,24-27,30-32,34,35,37,38] were included in the analysis of WHR and risk of colorectal cancer incidence. Comparison of the highest category of WHR with the lowest category revealed significant associations between higher WHR and increased risk of total colorectal cancer (RR 1.39, 95% CI 1.25, 1.53), colon cancer (RR 1.39, 95% CI 1.18, 1.63), and rectal cancer (RR 1.22, 95% CI 1.05, 1.42) (Figure 2b). The evidence of high heterogeneity were observed for total colorectal cancer (I2 = 51.2%, P=0.002), as well as for colon cancer (I2 = 60.2%, P = 0.004), while no heterogeneity was observed for rectal cancer (I2 = 0.0%, P=0.591). Subgroup analyses further identified the robustness of the association between abdominal obesity and CRC risk (Table 2). Stratifying by sex, the pooled RRs of CRC from male and female CRC studies for the highest vs. lowest categories of WHR level were 1.47 (95% CI, 1.25–1.73) and 1.30 (95% CI, 1.15–1.48) respectively. Stratifying by geographic region, the pooled RRs of CRC for the highest vs. lowest categories of WHR level were 1.26 (95% CI, 0.78–2.04) for studies conducted in Asia, 1.32 (95% CI, 1.13–1.54) for studies in the United States, 1.51 (95% CI, 1.29–1.76) for studies in Europe, and 1.61 (95% CI, 1.23–2.10) for studies in Australia. When we stratified the analysis by measured and self-reported CRC data, the pooled RRs of measured and self-reported CRC data were 1.53 (95% CI, 1.34–1.75) and 1.22 (95% CI, 1.08–1.38) for the highest vs. lowest categories of WHR levels respectively. Metaregression analysis showed that geographic region and sex were possible sources of heterogeneity. The sensitivity analyses omitting one study at a time and calculating the combined RRs for the remaining studies showed the combined RRs were not substantially affected by any single study (Figure 3b). The Begg’s and Egger’s test indicated no evidence of publication bias among the studies [Begg, P > |z| = 0.009; Egger, P=0.106; 95% CI, 0.248–2.419] (Figure 4b).

Discussion

This systematic review and meta-analysis aimed to examine the association between abdominal obesity and risk of total colorectal cancer, colon cancer, and rectal cancer, which was the first meta-analysis on this subject. We found evidence of an increased risk of total colorectal cancer, colon cancer, and rectal cancer with greater WC and WHR. There was obvious heterogeneity across those included studies. In some subgroup analysis, the heterogeneity declines (Table 2). However, the heterogeneity of other subgroup analysis remains high, which suggested that much of the heterogeneity in the meta-analysis was unable to be unexplained by subgroup analyses. In the metaregression analyses, the pooled risk estimates were similar when studies were stratified by those factors that were identified as possible sources of heterogeneity, and almost all the pooled risk estimates were statistically significant (Table 2). Thus, the heterogeneity had little influence on the overall evidence for the association between abdominal obesity and colorectal cancer. Strengths of the study are as follows: (a) To capture all relevant information, studies were included after a comprehensive, systematic search of the literature by a multidisciplinary team including specialists in gastrointestinal endoscopy, gastroenterology, and clinical epidemiology and using a broad search strategy. (b) Most of the included studies adjusted for nearly all the important covariates including age, education, family history of colorectal cancer, physical activity, alcohol intake, smoking etc. (c) The present meta-analysis is based on prospective studies, so we have effectively avoided recall and selection bias. Obesity is considered one of the important risk factors for many types of cancer, especially for CRC. However, the mechanisms that might underlie the association between excess weight and CRC remain unclear. Several mechanisms have been proposed to explain how general and central obesity enhances colorectal neoplasm risk. Previous studies have demonstrated that the fat itself can also influence CRC risk [39]. Adipocytes and preadipocytes could promote proliferation of CRC cells [40]. Fatty acid synthase overexpression has been shown to be associated with CRC phenotype [41]. Adipokines such as adiponectin, leptin are also associated with the risk of CRC. Adiponectin as an insulin-sensitizing agent and a negative regulator of angiogenesis is secreted mainly from visceral adipose tissue, which could inhibit CRC growth in animal models, and its circulating concentrations were associated with CRC risk in clinical trials [42]. Leptin could also favor CRC growth in vivo and in vitro experiment as a pleiotropic hormone being mitogenic, anti-apoptotic, pro-angiogenic, and proinflammatory in various cellular systems [43]. The relationship between circulating leptin concentrations and CRC risk has been demonstrated [44]. In addition, obesity, particularly abdominal obesity, is linked to insulin resistance, to hyperinsulinemia, and to the development of Type 2 diabetes [45,46]. IGF binding protein-1 (IGFBP-1) concentrations decrease with increasing adiposity [47], which may lead to elevated concentrations of free and bioavailable insulin-like growth factor-1 (IGF-1) [48]. The involvement of insulin and the subsequent up-regulated level of IGF-1 in colorectal carcinogenesis have been supported by experimental and clinical studies [49]. Available epidemiologic evidence suggests that abdominal obesity (as reflected by high WC and WHR) may be more predictive of colon cancer risk than overall obesity (high BMI) [50-53]. This positive association of WC or WHR with CRC remained even after adjustment for BMI [50-52]. The results indicated that higher WC and WHR levels were positively associated with CRC risk. Analyses stratified by the anatomical subsite suggested that both of higher BMI and WC levels caused an increasing risk for colon cancer and rectal cancer. When the analysis was stratified by sex, the results showed that higher WC and WHR levels were significantly positively associated with colorectal and colon cancer risk in both men and women. Stratifying by geographic region, the results revealed that higher BMI and WC levels were positively associated with CRC risk in the United States, Europe, or Australia. In addition, when the analysis was stratified by data collection, the result showed that there was an increased risk of CRC development associated with higher BMI and WC levels for both measured and self-reported data. However, several limitations in this meta-analysis should be considered. First, most of the included studies did not provide the risk estimates controlling for weight change during follow-up, and they could not exclude the impact of weight change during follow-up on the association between abdominal obesity and CRC. Second, although individual studies have considered a wide range of potential confounders in their analyses, we cannot fully exclude unknown or residual confounding factors which may have influence on our findings. Third, although our analysis indicate that both higher WC and WHR increase the risk of colorectal cancer, colon cancer, and rectal cancer, few studies have conducted further adjustments between abdominal obesity measurement and BMI to try to clarify their respective roles. Finally, as with any meta-analysis, publication bias is a matter of concern, because small studies with null results tend not to be published. Although there was no evidence of publication bias, we cannot exclude such bias because of low statistical power due to limited number of studies.

Conclusions

In summary, findings from this meta-analysis of prospective studies provide evidence that abdominal obesity may play an important role in the development of colorectal cancer. This positive association also exists in both men and women, different geographic region, and different anatomical site. Further large prospective studies are necessary to evaluate whether the association between central obesity and CRC is biased by BMI. (a) Pooled relative risk of CC associated with waist circumference; (b) Pooled relative risk of CC associated with waist to hip ratio; (c) Pooled relative risk of RC associated with waist circumference; (d) Pooled relative risk of RC associated with waist to hip ratio
Table S1

Quality assessment according to the nine-star Newcastle-Ottawa Scale (NOS)

Table S2

Detailed amounts of waist circumference and waist to hip ratio.

  49 in total

Review 1.  Obesity and insulin resistance.

Authors:  B B Kahn; J S Flier
Journal:  J Clin Invest       Date:  2000-08       Impact factor: 14.808

2.  The metabolic syndrome and risk of incident colorectal cancer.

Authors:  Rehana L Ahmed; Kathryn H Schmitz; Kristin E Anderson; Wayne D Rosamond; Aaron R Folsom
Journal:  Cancer       Date:  2006-07-01       Impact factor: 6.860

3.  Adipocytes and preadipocytes promote the proliferation of colon cancer cells in vitro.

Authors:  Sadahiro Amemori; Akifumi Ootani; Shigehisa Aoki; Takehiro Fujise; Ryo Shimoda; Takashi Kakimoto; Ryosuke Shiraishi; Yasuhisa Sakata; Seji Tsunada; Ryuichi Iwakiri; Kazuma Fujimoto
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2007-03       Impact factor: 4.052

Review 4.  Central obesity and risks of pre- and postmenopausal breast cancer: a dose-response meta-analysis of prospective studies.

Authors:  G-C Chen; S-J Chen; R Zhang; K Hidayat; J-B Qin; Y-S Zhang; L-Q Qin
Journal:  Obes Rev       Date:  2016-07-19       Impact factor: 9.213

5.  Operating characteristics of a rank correlation test for publication bias.

Authors:  C B Begg; M Mazumdar
Journal:  Biometrics       Date:  1994-12       Impact factor: 2.571

6.  A meta-analysis of body mass index and esophageal and gastric cardia adenocarcinoma.

Authors:  F Turati; I Tramacere; C La Vecchia; E Negri
Journal:  Ann Oncol       Date:  2012-08-16       Impact factor: 32.976

7.  Self-reported and measured anthropometric data and risk of colorectal cancer in the EPIC-Norfolk study.

Authors:  J Y Park; P N Mitrou; R H Keogh; R N Luben; N J Wareham; K-T Khaw
Journal:  Int J Obes (Lond)       Date:  2011-03-22       Impact factor: 5.095

Review 8.  Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions, and colorectal cancer.

Authors:  Manjinder S Sandhu; David B Dunger; Edward L Giovannucci
Journal:  J Natl Cancer Inst       Date:  2002-07-03       Impact factor: 13.506

9.  Comparison of associations of body mass index, abdominal adiposity, and risk of colorectal cancer in a large prospective cohort study.

Authors:  Marlen Keimling; Andrew G Renehan; Gundula Behrens; Beate Fischer; Albert R Hollenbeck; Amanda J Cross; Michael F Leitzmann
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-05-29       Impact factor: 4.254

10.  Body weight, fat distribution and colorectal cancer risk: a report from cohort studies of 134255 Chinese men and women.

Authors:  H Li; G Yang; Y-B Xiang; X Zhang; W Zheng; Y-T Gao; X-O Shu
Journal:  Int J Obes (Lond)       Date:  2013-06       Impact factor: 5.095

View more
  44 in total

1.  Circulating Biomarker Score for Visceral Fat and Risks of Incident Colorectal and Postmenopausal Breast Cancer: The Multiethnic Cohort Adiposity Phenotype Study.

Authors:  Loïc Le Marchand; Lynne R Wilkens; Ann M Castelfranco; Kristine R Monroe; Bruce S Kristal; Iona Cheng; Gertraud Maskarinec; Meredith A Hullar; Johanna W Lampe; John A Shepherd; Adrian Franke; Thomas Ernst; Unhee Lim
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-03-04       Impact factor: 4.254

2.  Uncoupling Hepatic Oxidative Phosphorylation Reduces Tumor Growth in Two Murine Models of Colon Cancer.

Authors:  Yongliang Wang; Ali R Nasiri; William E Damsky; Curtis J Perry; Xian-Man Zhang; Aviva Rabin-Court; Michael N Pollak; Gerald I Shulman; Rachel J Perry
Journal:  Cell Rep       Date:  2018-07-03       Impact factor: 9.423

3.  Adherence to Guideline-Recommended Cancer Screening in Stroke Survivors: A Nationwide Analysis.

Authors:  Marialaura Simonetto; Stephanie Rutrick; Natalie M LeMoss; Kelsey N Lansdale; Scott T Tagawa; Hooman Kamel; Neal Parikh; Babak B Navi
Journal:  J Stroke Cerebrovasc Dis       Date:  2022-01-13       Impact factor: 2.136

4.  Obesity Strongly Promotes Growth of Mouse MC38 Colon Cancer in an Orthotopic-syngeneic C57BL/6 Mouse Model.

Authors:  Kazuyuki Hamada; Yutaro Kubota; Yusuke Aoki; Norihiko Sugisawa; Jun Yamamoto; Yoshihiko Tashiro; Michael Bouvet; Takuya Tsunoda; Robert M Hoffman
Journal:  In Vivo       Date:  2022 Jul-Aug       Impact factor: 2.406

5.  The interaction between glycemic index, glycemic load, and the genetic variant ADIPOQ T45G (rs2241766) in the risk of colorectal cancer: a case-control study in a Korean population.

Authors:  Y-Thanh Lu; Madhawa Gunathilake; Jeonghee Lee; Jae Hwan Oh; Hee Jin Chang; Dae Kyung Sohn; Aesun Shin; Jeongseon Kim
Journal:  Eur J Nutr       Date:  2022-03-03       Impact factor: 4.865

Review 6.  Nutrient metabolism and cancer in the in vivo context: a metabolic game of give and take.

Authors:  Patricia Altea-Manzano; Alejandro M Cuadros; Lindsay A Broadfield; Sarah-Maria Fendt
Journal:  EMBO Rep       Date:  2020-09-23       Impact factor: 8.807

7.  Yogurt consumption and colorectal cancer incidence and mortality in the Nurses' Health Study and the Health Professionals Follow-Up Study.

Authors:  Karin B Michels; Walter C Willett; Rita Vaidya; Xuehong Zhang; Edward Giovannucci
Journal:  Am J Clin Nutr       Date:  2020-12-10       Impact factor: 7.045

8.  The effect of smoking, obesity and diabetes on recurrence-free and overall survival in patients with stage III colon cancer receiving adjuvant chemotherapy.

Authors:  Alex Croese; Richard Gartrell; Richard Hiscock; Margaret Lee; Peter Gibbs; Ian Faragher; Justin Yeung
Journal:  Cancer Rep (Hoboken)       Date:  2021-02-07

9.  Obesity and incident gastrointestinal cancers: overall body size or central obesity measures, which factor matters?

Authors:  Nahid Hashemi Madani; Arash Etemadi; Mahdi Nalini; Hossein Poustchi; Alireza Khajavi; Elahe Mirzazade; Hosna Mirfakhraei; Akram Pourshams; Masoud Khoshnia; Abdolsamad Gharavi; Shahin Merat; Moahammad E Khamseh; Reza Malekzadeh
Journal:  Eur J Cancer Prev       Date:  2021-05-01       Impact factor: 2.164

10.  Electro-acupuncture for central obesity: randomized, patient-assessor blinded, sham-controlled clinical trial protocol.

Authors:  Linda L D Zhong; Xingyao Wu; Tsz Fung Lam; Ying Ping Wong; Peihua Cao; Emily Yen Wong; Shipping Zhang; Zhaoxiang Bian
Journal:  BMC Complement Med Ther       Date:  2021-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.